ADVISORY, May 09, 2017 (GLOBE NEWSWIRE) --
| WHO: |
Emergent BioSolutions
Inc. (NYSE:EBS)
|
| |
|
| WHAT: |
Ribbon-cutting and tour of expanded Emergent BioSolutions’ Center
for |
| |
Innovation in Advancement Development and Manufacturing
(CIADM), |
| |
featuring speakers: |
| |
|
| |
Daniel J.
Abdun-Nabi |
| |
President & Chief Executive Officer, Emergent BioSolutions |
| |
|
| |
Rick A. Bright, Ph.D. |
| |
Director, Biomedical Advanced Research and Development Authority
(BARDA) |
| |
Deputy Assistant Secretary, Office of the Assistant Secretary for
Preparedness |
| |
and Response at the U.S. Department of Health and Human Services
(HHS) |
| |
|
| |
William H. Cole |
| |
President & CEO, Baltimore Development Corporation |
| |
|
| |
Secretary Mike Gill |
| |
Department of Commerce, State of Maryland |
| |
|
| WHY: |
Five years ago, Emergent and BARDA entered into a public-private
partnership |
| |
to establish a CIADM intended to develop and manufacture
medical |
| |
countermeasures to protect the public in health
emergencies. |
| |
|
| |
This Wednesday, Emergent will unveil its newly expanded Baltimore
CIADM |
| |
facility – one of only three HHS-designated Centers in the United
States. The |
| |
112,000-square-foot facility, comprised of laboratory, manufacturing
and office |
| |
space, offers flexible manufacturing of drug substance from
microbial, cell |
| |
culture, or viral production platforms. Its capabilities for
advanced |
| |
development and manufacturing of medical countermeasures were
designed to |
| |
help address the U.S. government’s national security and public
health needs. |
| |
The facility is equipped with disposable manufacturing technology to
enable |
| |
Emergent to meet the government’s domestic preparedness priorities
and |
| |
needs on a cost-effective, reliable and sustainable basis. |
| |
|
| |
Since its inception, the Emergent CIADM has been awarded four task
orders by |
| |
BARDA to develop Ebola and Marburg therapeutics and a Zika
vaccine. |
| |
Emergent has also successfully manufactured some of its product
candidates |
| |
at the CIADM and an Ebola vaccine candidate as part of a
third-party |
| |
collaboration. |
| |
|
| WHERE: |
Emergent BioSolutions Bayview Campus |
| |
5901 East Lombard St. |
| |
Baltimore, MD 21224 |
| |
|
| WHEN: |
Wednesday, May 10, 2017 |
| |
9 a.m. to 11 a.m. |
About Emergent BioSolutions
Emergent BioSolutions Inc. is a global life sciences company seeking to protect and enhance life by focusing on providing specialty
products for civilian and military populations that address accidental, intentional, and naturally emerging public health threats.
Through our work, we envision protecting and enhancing 50 million lives with our products by 2025. Additional information about the
company may be found at www.emergentbiosolutions.com. Follow us @emergentbiosolu.
Media Contact: Lynn Kieffer Vice President, Corporate Communications 240-631-3391 kiefferl@ebsi.com
